You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 22, 2025

Details for Patent: 10,624,850


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,624,850 protect, and when does it expire?

Patent 10,624,850 protects APONVIE and CINVANTI and is included in two NDAs.

Summary for Patent: 10,624,850
Title:Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Abstract:Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Inventor(s):Thomas B. Ottoboni, Han Han
Assignee:Heron Therapeutics LLC
Application Number:US15/965,638
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

United States Patent 10,624,850: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 10,624,850, hereafter referred to as the '850 patent, is part of a suite of patents often cited in patent infringement cases. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Patent Overview

The '850 patent is one of several patents held by companies involved in various legal disputes, particularly in the pharmaceutical industry. It is categorized under the Patent Laws of the United States, specifically under 35 U.S.C. §§ 100 et seq.[2][5].

Scope of the Patent

The scope of the '850 patent is defined by its claims, which outline the specific inventions or innovations it protects. In patent infringement cases, it is crucial to determine whether a product or process meets or embodies all elements of one or more claims of the patent in question.

Claims Analysis

The claims of the '850 patent are detailed and specific, covering various aspects of the invention. Here are some key points to consider:

  • Claim Elements: Each claim lists the essential elements that must be present for an infringement to occur. For example, if a product or process includes all the elements described in a claim, it could be considered an infringement[2][5].
  • Claim Types: Patents can have different types of claims, such as independent claims and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims[3].

Patent Landscape

The '850 patent is part of a larger patent landscape that includes other related patents. Here’s how it fits into this broader context:

Related Patents

The '850 patent is often mentioned alongside other patents in the same family, such as U.S. Patent Nos. 9,561,229, 9,808,465, 9,974,742, 9,974,793, 9,974,794, 10,500,208, 10,953,018, and 11,173,118. These patents collectively protect a range of inventions and are frequently cited in infringement cases[2][5].

Patent Analytics

To understand the full scope of protection offered by the '850 patent and its related patents, companies use patent analytics. This involves creating a Claim Coverage Matrix to identify which patents and claims are actively protecting the intellectual property and where gaps or opportunities exist[3].

Scope Concepts and Claim Charts

Patent analytics tools categorize patents by claims and scope concepts, which are overarching themes that link claims on similar patents. This helps in filtering, searching, and analyzing large numbers of patent claims. Interactive claim charts generated by tools like ClaimScape® facilitate the review of patent coverage with technical experts, engineers, and management[3].

Infringement Cases

The '850 patent has been involved in several infringement cases, highlighting its importance in protecting intellectual property.

Example Cases

  • Heron vs. Fresenius: In this case, Heron alleged that Fresenius’s submission of an Abbreviated New Drug Application (ANDA) to the FDA constituted infringement of the '850 patent, among others. The complaint detailed how the proposed generic product met or embodied all elements of one or more claims of the '850 patent[2].
  • Heron vs. Mylan: Similar allegations were made against Mylan, where Heron claimed that Mylan’s ANDA submission and certification constituted infringement of the '850 patent and other related patents[5].

Public Interest and Jurisdiction

In patent infringement cases involving the '850 patent, courts consider various public interest factors and jurisdictional issues.

Public Interest Factors

  • Local Interest: This factor is often neutral in patent infringement cases, as these are matters of national concern rather than local interest[4].
  • Familiarity with Related Patents: Courts consider the familiarity of the trial judge with related patents and facts from prior litigation, which can weigh in favor of transferring the case to a different forum[4].

Key Takeaways

  • Claims Analysis: Understanding the specific claims of the '850 patent is crucial for determining infringement.
  • Patent Landscape: The '850 patent is part of a larger family of patents that collectively protect a range of inventions.
  • Patent Analytics: Tools like Claim Coverage Matrix and Claim Charts are essential for analyzing and managing patent portfolios.
  • Infringement Cases: The '850 patent has been involved in several high-profile infringement cases, highlighting its significance in protecting intellectual property.

FAQs

What is the '850 patent, and what does it protect?

The '850 patent is a United States patent that protects specific inventions or innovations, particularly in the pharmaceutical industry. Its claims outline the essential elements that must be present for an infringement to occur.

How is the '850 patent related to other patents?

The '850 patent is often cited alongside other patents in the same family, such as U.S. Patent Nos. 9,561,229, 9,808,465, and others. These patents collectively protect a range of inventions.

What is the role of patent analytics in managing the '850 patent?

Patent analytics involves creating a Claim Coverage Matrix and using tools like ClaimScape® to categorize patents by claims and scope concepts. This helps in identifying gaps or opportunities in the patent portfolio.

What are some notable infringement cases involving the '850 patent?

Notable cases include Heron vs. Fresenius and Heron vs. Mylan, where the '850 patent was alleged to have been infringed by the submission of ANDA applications to the FDA.

How do courts determine jurisdiction in patent infringement cases involving the '850 patent?

Courts consider various public interest factors, including the familiarity of the trial judge with related patents and facts from prior litigation, to determine the appropriate jurisdiction for the case.

Sources

  1. USPTO Search: Find existing patents, published patent applications and other published patent documentation.
  2. IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT: Heron vs. Fresenius patent infringement case.
  3. Patent Analytics | Intellectual Property Law: Patent analytics and claim coverage matrix.
  4. UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY: Public interest factors and jurisdiction in patent infringement cases.
  5. IN THE UNITED STATES DISTRICT COURT: Heron vs. Mylan patent infringement case.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,624,850

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Heron Theraps Inc APONVIE aprepitant EMULSION;INTRAVENOUS 216457-001 Sep 16, 2022 RX Yes Yes 10,624,850 ⤷  Try for Free A METHOD OF ADMINISTERING APREPITANT FOR PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING ⤷  Try for Free
Heron Theraps Inc CINVANTI aprepitant EMULSION;INTRAVENOUS 209296-001 Nov 9, 2017 RX Yes Yes 10,624,850 ⤷  Try for Free TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.